Phase 1b Study of IC14 in Arrhythmogenic Cardiomyopathy
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs Atibuclimab (Primary)
- Indications Arrhythmogenic right ventricular dysplasia
- Focus Adverse reactions; Proof of concept
- Sponsors Implicit Bioscience
- 22 Nov 2024 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
- 22 Nov 2024 Planned primary completion date changed from 1 Feb 2025 to 1 Aug 2025.
- 29 Mar 2024 Status changed from not yet recruiting to recruiting.